1. Pink Sheet

Drug Development Questions Dominate Hahn's Confirmation, Despite Talk About E-Cigs

 
• By Michael Cipriano

A plurality of the questions from the Senate HELP Committee at Stephen Hahn's confirmation hearing to head the US FDA focused on drug development issues, despite the time lawmakers spent discussing the agency's regulation of e-cigarettes.

Stephen Hahn, President Trump’s nominee for commissioner of the FDA, at his Senate confirmation hearing today
Stephen Hahn received a series of questions on drug development at his Senate confirmation hearing. • Source: Derrick Gingery

Even though much of Stephen Hahn's 20 November Senate confirmation hearing to become commissioner of the US Food and Drug Administration focused on e-cigarettes, a plurality of actual questions directed to the MD Anderson chief medical executive focused on drug development issues, similar to Scott Gottlieb's confirmation hearing in 2017.

Many members of the Senate Health, Education, Labor and Pensions Committee discussed the FDA's regulation of e-cigarettes, but a Pink Sheet analysis of the 67 questions asked by committee members...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

US FDA Meeting Drought Ends … With A Vengeance

 
• By Michael McCaughan

The first 100 days of the Trump Administration were notable for an extraordinary decline in the number of public meetings hosted by the US Food and Drug Administration. But the schedule changed quickly.

US FDA Makary’s Pharma CEO Tour Goes Against Transparency Rhetoric

 
• By Sarah Karlin-Smith

FDA Commissioner Martin Makary will give industry a new avenue for access and influence despite his and HHS Secretary Robert F. Kennedy Jr.’s claims that the pharma-FDA relationship is too cozy.

Pink Sheet Podcast: US FDA’s Big Vaccine Policy Week

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors discuss the new clinical trial requirements that the FDA announced for COVID-19 vaccines, the updated label for Novavax’s newly approved COVID-19 vaccine, and other vaccine-related events that were part of a busy week for policy in the sector.

US FDA Punts On New COVID-19 Framework’s Impact On Fall Shots

 
• By Sarah Karlin-Smith

The FDA’s advisors split on whether to update COVID-19 vaccines for the fall. The agency refused to discuss the impact of the new vaccine framework on availability.

More from Agency Leadership